- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2397-768X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP ; volume:6 ; number:1 ; day:23 ; month:11 ; year:2022 ; pages:1-7 ; date:12.2022
npj precision oncology ; 6, Heft 1 (23.11.2022), 1-7, 12.2022
- Urheber
-
McFall, Thomas
Trogdon, Michael
Guizar, Anita C.
Langenheim, John F.
Sisk-Hackworth, Laura
Stites, Edward C.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-022-00329-w
- URN
-
urn:nbn:de:101:1-2023020508591484021493
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- McFall, Thomas
- Trogdon, Michael
- Guizar, Anita C.
- Langenheim, John F.
- Sisk-Hackworth, Laura
- Stites, Edward C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
The relationship between oncogenic KRas and wild-type Ras activity and signaling
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
K-Ras protein as a drug target
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Untersuchung der GAP-katalysierten GTP-Hydrolysereaktion von Ras und Rap
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Untersuchung der GAP-katalysierten GTP-Hydrolysereaktion von Ras und Rap
Excited-state observation of active K-Ras reveals differential structural dynamics of wild-type versus oncogenic G12D and G12C mutants
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
K-Ras prenylation as a potential anticancer target
MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
The relationship between oncogenic KRas and wild-type Ras activity and signaling
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
K-Ras protein as a drug target
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Untersuchung der GAP-katalysierten GTP-Hydrolysereaktion von Ras und Rap
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Untersuchung der GAP-katalysierten GTP-Hydrolysereaktion von Ras und Rap
Excited-state observation of active K-Ras reveals differential structural dynamics of wild-type versus oncogenic G12D and G12C mutants
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
K-Ras prenylation as a potential anticancer target
MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
The relationship between oncogenic KRas and wild-type Ras activity and signaling
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
K-Ras protein as a drug target
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Untersuchung der GAP-katalysierten GTP-Hydrolysereaktion von Ras und Rap
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Untersuchung der GAP-katalysierten GTP-Hydrolysereaktion von Ras und Rap
Excited-state observation of active K-Ras reveals differential structural dynamics of wild-type versus oncogenic G12D and G12C mutants
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
K-Ras prenylation as a potential anticancer target